INTEGRATED MICROFLUIDIC PLATFORM FOR PROTEOMIC AND GENETIC EXOSOME DETECTION

Project description

An exosome detection platform for cancer diagnosis

Liquid biopsy is a non-invasive approach for personalised cancer diagnosis and relies on circulating tumour cells and tumour DNA. However, extracellular vesicles termed exosomes are emerging as promising biomarkers for prompt cancer detection. To facilitate routine exosome analysis in the clinic, scientists of the EU-funded IMPED project propose to develop a next-generation technology capable of extracting and analysing exosomes from liquid biopsies or serum samples at the proteomic and genomic levels. The technology will be the first to combine both intra- and extra-vesicle detection on a single platform, offering important insight into precision cancer management on an individual patient basis.

Field of science

• /natural sciences/biological sciences/biochemistry/biomolecules/proteins/proteomics
• /natural sciences/physical sciences/classical mechanics/fluid mechanics/microfluidics
• /medical and health sciences/clinical medicine/cancer

Programme(s)

• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2019 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2019
See other projects for this call

Funding Scheme

MSCA-IF-GF - Global Fellowships

Coordinator

INSTITUT CURIE

Address

Rue D'ulm 26
75231 Paris
France

Activity type

Research Organisations

EU contribution

€ 244 385,28

Partners (1)

ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING MCGILL UNIVERSITY

Canada

Address

845 Sherbrooke Street West
H3A0G4 Montreal

Activity type

Higher or Secondary Education Establishments